Navigation Links
Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
Date:4/25/2008

LA JOLLA, Calif., April 25 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), a biotechnology company developing medical products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that the Company's management and clinical and regulatory consultants met on April 16 with members of the United States Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. The purpose of the meeting was to discuss the appropriate regulatory pathway for filing a marketing application of ATPace(TM) as an antiarrhythmic drug for the acute termination of paroxysmal supraventricular tachycardia (PSVT).

Based on discussions held during the meeting and prior written communications between Duska and the FDA, the Company believes that the FDA would consider a New Drug Application (NDA) under section 505(b)(2) for ATPace(TM) subject to additional clinical data to be furnished by the Company. The 505(b)(2) NDA relies in part upon relevant published data obtained by entities other than the Company.

Dr. James Kuo, Duska's Chairman and CEO, said, "I am pleased to report that this meeting with the FDA was both positive and constructive. Together with our CRO, Cato Research, Inc., we have already commenced activities aimed at the generation of the supplemental data requested by the FDA. The 505(b)(2) NDA filing provides an expedited route for potential approval of ATPace(TM)," he added.

Dr. Amir Pelleg, Duska's President and Chief Scientific Officer, stated, "It has been our goal to commercialize the first ATP-based drug in the United States and I believe we are now much closer to attaining that goal as a result of this meeting. Formulations of ATP, which is the active ingredient in ATPace(TM), have been used for over 50 years in Europe in the treatment of PSVT. I am confident that our drug would manifest a safety and efficacy profile similar to that
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
2. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
3. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
4. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
5. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
6. Antisense therapeutics scientist out to pull more big deals
7. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
8. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
9. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
10. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
11. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi ... that influence the risk for developing prostate cancer, according to ... , Prostate cancer is the most common non-skin cancer in ... with the disease in his lifetime. Family history is the ... brother or father with prostate cancer is twice as likely ...
(Date:9/17/2014)... People with facial paralysis are perceived as being ... universal language of facial expression, a new study from ... The findings highlight the important role the face plays ... prejudice against those with facial paralysis because of their ... in the College of Liberal Arts at Oregon State ...
(Date:9/17/2014)... Tools4ever, the market leader ... and Boston Software Systems, leader in healthcare ... Under the agreement, Tools4ever will use ... within its identity and password management solutions. ... automation platforms that streamline complex processes and ...
(Date:9/17/2014)... September 17, 2014. Kessler Foundation is the recipient ... the International Progressive Multiple Sclerosis (MS) Alliance. ... Traumatic Brain Injury Research, is principal investigator of ... of cognitive rehabilitation in individuals with progressive multiple ... grants awarded by the Alliance to investigators in ...
(Date:9/17/2014)... Gerontological Society of America (GSA) invites all journalists ... the country,s largest interdisciplinary conference in the field ... Washington, DC. Media representatives may register free of charge. ... the five-day gathering at the Walter E. Washington Convention ... 2014 is "Making Connections: From Cells to Societies" and ...
Breaking Medicine News(10 mins):Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
... ... Innovation and Growth , ... (PRWEB) June 21, 2010 -- DKI Direct ( http://www.dkidirect.com ), a leading Patient ... Chief Marketing Officer. Lewis will lead and build the marketing efforts for both existing ...
... viral for bacterial infections, review found , MONDAY, ... one who can,t always tell if your child has ... for antibiotics: Pediatricians say this is the most common ... Other common missed or mistaken diagnoses include those involving ...
... and cost-effective when targeted to high-risk patients, according ... the official journal of the American Gastroenterological Association ... be excessively costly or even harmful. "Surveillance ... that has the potential to decrease the burden ...
... something is due to our genes and how much is ... academic journal Addiction shows that the case is ... drugs, for two related reasons. First, a young woman ... to choose friends who smoke, drink, or use drugs, thereby ...
... in the journal Addiction reveals that drunkenness increases ... a strong inclination to suppress anger. The two ... reduces the risk of drawing erroneous conclusions about cause and ... of evidence suggesting that drinking may in fact inflict physical ...
... ... because of a small number of adverse event reports received by the FDA from users ... and its safety if used as directed. , ... (PRWEB) June 21, 2010 -- EphedrineHydrochloride.com is pleased to announce ...
Cached Medicine News:Health News:DKI Direct Appoints Greg Lewis as Chief Marketing Officer 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 3Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:New research shows peer drug use may increase an individual's genetic tendency to use drugs 2Health News:Ephedrine Hydrochloride.com Launches Review Site Examining Ephedrine HCL & Ephedra Based Diet Pills 2
(Date:9/17/2014)... and SAN JOSE, Calif. , Sept. 17, ... named as a laureate of The Tech Awards 2014, ... to benefit humanity and spark global change. The Tech Awards, ... presented by Applied Materials, Inc., selected Gradian as one of ... Photo - http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips ...
(Date:9/17/2014)... India , September 17, 2014 ... antagonist, GRC 17536, has shown positive data in a ... painful diabetic neuropathy , Glenmark ... Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has ... placebo controlled, multi-centre, proof of concept study conducted on ...
(Date:9/17/2014)... YORK , Sept. 17, 2014  Millions of people ... cervical disc disease. Recently the FDA approved ... cervical disc, an innovative implant device developed by Spinal Kinetics, ... resulting in neck and or arm pain. Hospital for Special ... is the only hospital in New York City ...
Breaking Medicine Technology:Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
... SweetSpot Diabetes Care, Inc. announced today it has ... Drug Administration (FDA) for the SweetSpot Diabetes Data Management ... understand and use blood glucose meter data to diagnose ... many patients and health care providers to develop this ...
... , Inc. (OTC: HEWA), a leading VIPPS-accredited, ... pre-order program to enable consumers immediate access to Atorvastatin ( ... the medication at up to 50 percent less than ... "We will be one of the earliest and most ...
Cached Medicine Technology:SweetSpot Diabetes Care Receives FDA 510(k) Clearance for SweetSpot Diabetes Data Management Service 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 3
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: